Lys Therapeutics is pleased to participate in the EMBO Workshop “Advances in Stroke-Immunology: From molecular mechanisms to clinical translation,” taking place in Munich, Germany, from April 27 to 30, 2026.

This meeting is a great opportunity to engage with leading experts in stroke immunology and discuss how neuroinflammation, blood-brain barrier dysfunction, and neurovascular injury can be translated into innovative therapeutic strategies.

At Lys Therapeutics, we are advancing LYS241, our first-in-class monoclonal antibody designed to block the pathological tPA-NMDAr interaction, with the ambition to protect the neurovascular unit and address key mechanisms driving ischemic stroke progression.

#Stroke #StrokeImmunology #Neuroinflammation #BloodBrainBarrier #NeurovascularUnit #Biotech #LYS241 #LysTherapeutics